



COVIDIEN

Deutsche Bank 36th Annual Health Care Conference

Joe Almeida | President – Medical Devices

Forward-Looking Statements

This presentation contains certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to risks, uncertainty and changes in circumstances, which may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. All statements contained herein that are not clearly historical in nature are forward-looking and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements.

The forward-looking statements in this presentation may include statements addressing the following subjects: future financial condition and operating results, economic, business, competitive and/or regulatory factors affecting our business. Any of the following factors may affect our future results:

- Our ability to effectively introduce and market new products or keep pace with advances in technology
- The reimbursement practices of a small number of large public and private insurers
- Cost-containment efforts of customers, purchasing groups, third-party payors and governmental organizations
- Intellectual property rights disputes
- Complex and costly regulation, including healthcare fraud and abuse regulations and the Foreign Corrupt Practices Act
- Manufacturing or supply chain problems or disruptions
- Recalls or safety alerts and negative publicity relating to Covidien or its products

Forward-Looking Statements (cont.)

- Product liability losses and other litigation liability
- Prices for oil, gas and other commodities
- Divestitures of some of our businesses or product lines
- Our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses
- Competition
- Risks associated with doing business outside of the United States
- Foreign currency exchange rates
- Environmental remediation costs

These are examples of factors, among others, that could cause actual results to differ materially from those described in the forward-looking statements. In addition, our historical combined financial information is not necessarily representative of the results we would have achieved as an independent, publicly-traded company and may not be a reliable indicator of our future results. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements whether as a result of new information, future events or otherwise. More detailed information about these and other factors is set forth in Covidien's Annual Report on Form 10-K and other periodic filings with the SEC.


Medical Devices Update

2010 sales growth 11% (8% operational);
YTD 2011 13% (12% operational)

2011 sales growth paced by vascular,
energy, oximetry & monitoring products

ev3 integration proceeding as planned;
slightly accretive to EPS in 2011

Procedure trends consistent with recent
past; U.S. generally flat, with some growth
projected in bariatric and general surgery




* Operational growth, net sales growth excluding the impact of foreign currency exchange, is a non-GAAP measure.

Medical Devices – YTD Net Sales

\$ Millions	YTD		Operational
<u>Product Line</u>	<u>FY 2011</u>	<u>% Change</u>	<u>Growth* %</u>
Endomechanical	\$1,125	5	5
Soft Tissue Repair	441	2	2
Energy	553	15	14
Oximetry & Monitoring	416	11	11
Airway & Ventilation	371	(9)	(9)
Vascular	665	92	91
Other Products	<u>183</u>	<u>(9)</u>	<u>(14)</u>
Total Medical Devices	\$3,754	13	12

* Operational growth, net sales growth excluding the impact of foreign currency exchange, is a non-GAAP measure.

2010 – 2011 New Product Launches Medical Devices



Medical Devices Will Deliver Growth By...



Executing on recent key product launches across the portfolio



Using clinical and economic evidence to accelerate our innovative technology pipeline



Integrating recent acquisitions to accelerate growth



Funding an aggressive Emerging Markets growth plan

Medical Devices will deliver innovative solutions by demonstrating *clinical and economic* evidence

Covidien Senior Leadership Transition

No significant change to Covidien's strategic direction

- Accelerate top-line growth
- Drive innovation with increased R&D
- Deliver clinically advantaged products and solutions at the lowest cost possible
- Create cost headroom
- Short-term focus on tuck-in acquisitions
- Aggressively expand in emerging markets



COVIDIEN

Deutsche Bank 36th Annual Health Care Conference

Joe Almeida | President – Medical Devices



Appendix

Non-GAAP Financial Measures

This presentation discusses measures which may be considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with generally accepted accounting principles. The definition of these non-GAAP measures may differ from similarly titled measures used by others.

The Company generally uses non-GAAP financial measures to facilitate management’s internal comparisons to Covidien’s historical operating results, to competitors’ operating results, and to provide greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including to evaluate Covidien’s operating performance and to determine management incentive compensation.

The Company presents its operating margin forecast before special items to give investors a perspective on the expected underlying business results. Because the Company cannot predict the timing and amount of such items and the associated charges or gains that will be recorded in the Company’s financial statements, it is difficult to include the impact of those items in the forecast.

The following is a list of the non-GAAP financial measures which may be discussed in this presentation:

Adjusted Net Sales: Net sales excluding sales of oxycodone hydrochloride extended-release tablets (Oxy ER).

Adjusted Operating Income: Operating income excluding Oxy ER and excluding charges or income for class action and shareholder settlements, net of insurance recoveries, restructuring charges, legal settlements, licensing fees, loss on divestiture, environmental charges, transaction costs and in-process R&D.

Adjusted Operating Income Margin: Adjusted Operating Income / Adjusted Net Sales (expressed as a percentage).

Free Cash Flow: Net cash provided by continuing operating activities excluding class action and shareholder settlements minus capital expenditures.

Operational sales growth: Year over year adjusted net sales increase excluding the impact of foreign exchange, expressed as a percentage.

Return on Invested Capital (ROIC): Adjusted income from continuing operations plus after-tax interest expense divided by total assets less total liabilities. Total assets exclude cash and cash equivalents, notes receivable and tax related assets. Total liabilities exclude tax related liabilities and debt.

Additional information is available in the Investor Relations section of our website www.covidien.com

Medical Devices – YTD Net Sales

\$ Millions	YTD		% Change	Operational
<u>Product Line</u>	<u>FY 2011</u>	<u>% Change</u>	<u>Currency</u>	<u>Growth* %</u>
Endomechanical	\$1,125	5	-	5
Soft Tissue Repair	441	2	-	2
Energy	553	15	1	14
Oximetry & Monitoring	416	11	-	11
Airway & Ventilation	371	(9)	-	(9)
Vascular	665	92	1	91
Other Products	<u>183</u>	<u>(9)</u>	<u>5</u>	<u>(14)</u>
Total Medical Devices	\$3,754	13	1	12

* Operational growth, net sales growth excluding the impact of foreign currency exchange, is a non-GAAP measure.